FDA lifts partial clinical hold on Cell Therapeutics drug

|By:, SA News Editor

The FDA has lifted a partial clinical hold on Cell Therapeutics' (CTIC +3.1%) Tosedostat blood cancer drug.

The agency placed the hold in June following the death of a patient in a trial in which the treatment was given along with chemotherapy.

Tosedostat is in Phase II trials in elderly patients with newly diagnosed and relapsed acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). (PR)